Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2017-10-26 Share Issue/Capital Cha…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document title is "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references articles from the French Commercial Code and the AMF (Autorité des marchés financiers) general regulation, which mandates this disclosure. The content provides a table detailing the number of shares and voting rights as of a specific date (30/09/2017). This type of mandatory disclosure regarding the total number of shares and voting rights is a specific regulatory filing related to capital structure and ownership thresholds, but it is not a general share issue (SHA) or a transaction in own shares (POS). It is a periodic update on the total outstanding capital structure for regulatory transparency. Given the options, this specific disclosure about the total number of shares and voting rights aligns most closely with notifications related to capital structure changes or major shareholding notifications, but since it is a mandatory periodic disclosure of the total count, it often falls under general regulatory reporting. However, looking closely at the definitions, it is a direct report of capital structure data. Since there isn't a perfect fit for 'Total Voting Rights Disclosure', I must choose the closest category. It is not a general share issue (SHA) as it reports the current total, not an issuance event. It is not a Major Shareholding Notification (MRQ) which reports changes in ownership *by* a shareholder crossing a threshold. It is a direct report of the total capital structure. In many contexts, this specific filing type is classified under general regulatory announcements or sometimes linked to capital changes. Given the options, and recognizing this is a mandatory disclosure about the total capital base, it is a specific type of regulatory filing. Since it is a direct report of capital structure data, and not an announcement *about* a report, I will classify it based on the content. The closest fit among the provided codes for a direct report on the total number of shares and voting rights, which is a fundamental aspect of capital structure reporting, is often grouped with Share Issue/Capital Change (SHA) or treated as a general Regulatory Filing (RNS). Since it is a direct, structured report of capital data, and not just a brief announcement, I will lean towards the most specific capital-related category that isn't an issuance event. However, the content is purely informational about the current state of voting rights, which is a key component of regulatory transparency. Given the strict definitions, and the lack of a specific 'Voting Rights Disclosure' code, RNS (Regulatory Filings) is the safest fallback for specific, non-standard regulatory disclosures. But, since it is a direct report of the total share count, it is fundamentally about the capital structure. Let's re-evaluate: SHA is 'Share Issue/Capital Change'. This document reports the *result* of capital changes (like the 20,000 shares mentioned) and the resulting total. It is a direct report of the capital base. I will classify this as a specific regulatory filing that reports on the capital base, which is often grouped with general regulatory filings (RNS) when a more specific code isn't available, as it doesn't fit 10-K, IR, ER, or DVA (which is voting *results*). I will use RNS as the best fit for a specific, mandatory, non-standard regulatory disclosure.
2017-10-26 French
Abivax prasentiert neue Daten uber die Wirksamkeit seines Immunverstarkers ABX196 im Leberkrebs-Tiermodell auf dem World Vaccine Congress
Regulatory Filings Classification · 1% confidence The document is a press release dated October 12, 2017, announcing that ABIVAX will present new preclinical data regarding its compound ABX196 at the World Vaccine Congress. It details the positive results (tumor reduction, survival rates) from a mouse model for hepatocellular carcinoma. This type of announcement, focusing on scientific study results being presented at a conference, is best classified as an Earnings Release (ER) if it were summarizing financial performance, but since it is purely scientific/clinical data presentation news, it falls under the general category of corporate news that doesn't fit the specific financial reports (10-K, IR, MRQ, etc.). Given the options, this is a general corporate announcement about research findings, which often accompanies or precedes formal financial reporting periods. However, it is not a formal regulatory filing like a 10-K or IR. It is a news release detailing scientific progress. Since there is no specific category for 'Research Update' or 'Conference Presentation Announcement', and it is not a formal financial report, the most appropriate general category for significant corporate news that doesn't fit elsewhere is 'Regulatory Filings' (RNS) or potentially 'Earnings Release' (ER) if the context implied it was part of a quarterly update cycle, but here it is clearly about data presentation. Given the structure (DGAP-News, Corporate | Date/Time, Headline), it functions as a general corporate news release. I will classify it as RNS as the fallback for significant, non-standard corporate news, although it strongly resembles an ER in format but not content (no financials). Upon review, 'ER' is for initial announcement of *financial* results. This is an announcement of *study results*. Therefore, RNS is the best fit as a general regulatory/corporate news announcement.
2017-10-12 German
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release dated October 12th, 2017, announcing the presentation of preclinical data regarding the efficacy of ABX196 in a liver cancer model at the World Vaccine Congress. It details scientific findings, quotes researchers, and discusses future clinical development plans. This type of announcement, which releases key operational and scientific updates outside of mandated periodic financial reports (like 10-K or IR), fits best under the general category for regulatory announcements or press releases that don't match a more specific category like Earnings Release (ER) or Capital Update (CAP). Since it is a scientific/operational update announcement, and not a formal financial report, it is classified as a Regulatory Filing (RNS) as the most appropriate general category for non-standard, material company news releases.
2017-10-12 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Investor Presentation Classification · 1% confidence The document is a press release dated October 12, 2017, announcing that ABIVAX will present new preclinical data on its immune stimulant ABX196 at the World Vaccine Congress. It details scientific findings (tumor reduction, survival rates, immune response) and quotes management and external experts regarding the potential of the compound, especially in combination with checkpoint inhibitors. This type of announcement, focusing on scientific data presentation at a conference and providing key results without being a full regulatory financial report (like 10-K or IR), strongly aligns with an Investor Presentation (IP) or a general press release about research progress. Since it is a detailed announcement of scientific results intended for investors and the scientific community, 'Investor Presentation' (IP) is the most fitting category, as it often encompasses press releases detailing significant R&D milestones presented at conferences. It is not a formal financial filing (10-K, IR, ER) nor a simple announcement of a report release (RPA).
2017-10-12 French
ABIVAX erweitert Wissenschaftlichen Beirat durch Ernennung von Prof. Christian Brechot, einem anerkannten Virologen und ehemaligen Prasidenten des Institut Pasteur
Board/Management Information Classification · 1% confidence The document is a press release dated October 5, 2017, announcing the appointment of Prof. Christian Bréchot to ABIVAX's Scientific Advisory Board. The text uses keywords like "DGAP-News," "Corporate News," and announces a specific personnel change ("Personalie"). This type of announcement, detailing changes in senior personnel or advisory boards, aligns best with the 'Board/Management Information' category (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2017-10-05 German
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 1% confidence The document is a press release dated October 5, 2017, announcing the appointment of Professor Christian Bréchot to ABIVAX's Scientific Committee. This type of announcement concerns changes in key personnel or advisory bodies, which aligns directly with the definition of Board/Management Information (MANG). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a dividend notice (DIV). It is a specific corporate event announcement.
2017-10-05 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.